[
  {
    "ts": null,
    "headline": "Are Wall Street Analysts Predicting Quest Diagnostics Stock Will Climb or Sink?",
    "summary": "Quest Diagnostics has outperformed the broader market over the past year, and analysts are moderately optimistic about the stock’s prospects.",
    "url": "https://finnhub.io/api/news?id=9f4f4e75590813d3c47bf3755436281b2ec943ab1944665f27e19870c3fb9053",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756213245,
      "headline": "Are Wall Street Analysts Predicting Quest Diagnostics Stock Will Climb or Sink?",
      "id": 136530552,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DGX",
      "source": "Yahoo",
      "summary": "Quest Diagnostics has outperformed the broader market over the past year, and analysts are moderately optimistic about the stock’s prospects.",
      "url": "https://finnhub.io/api/news?id=9f4f4e75590813d3c47bf3755436281b2ec943ab1944665f27e19870c3fb9053"
    }
  },
  {
    "ts": null,
    "headline": "Corewell Health and Quest Diagnostics to Enter into Joint Venture Providing Enhanced Laboratory Services in Michigan",
    "summary": "Corewell Health and Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, have signed a definitive agreement to enter into a joint venture to expand access to innovative, quality and affordable laboratory services in Michigan.",
    "url": "https://finnhub.io/api/news?id=caccbde700ae70b9cec8610e57073c7c865d9181964543b4f561576d52586fd7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756213200,
      "headline": "Corewell Health and Quest Diagnostics to Enter into Joint Venture Providing Enhanced Laboratory Services in Michigan",
      "id": 136526098,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DGX",
      "source": "Yahoo",
      "summary": "Corewell Health and Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, have signed a definitive agreement to enter into a joint venture to expand access to innovative, quality and affordable laboratory services in Michigan.",
      "url": "https://finnhub.io/api/news?id=caccbde700ae70b9cec8610e57073c7c865d9181964543b4f561576d52586fd7"
    }
  },
  {
    "ts": null,
    "headline": "FDA grants breakthrough device designation for Quest Diagnostics’ MRD test",
    "summary": "The liquid biopsy test has been developed by experts in cancer genomics.",
    "url": "https://finnhub.io/api/news?id=0b9cb6a85f6a58d17fe4b4b956a34a556a2506285f0d4ca81eef84d92e7ce41a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756204730,
      "headline": "FDA grants breakthrough device designation for Quest Diagnostics’ MRD test",
      "id": 136524226,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DGX",
      "source": "Yahoo",
      "summary": "The liquid biopsy test has been developed by experts in cancer genomics.",
      "url": "https://finnhub.io/api/news?id=0b9cb6a85f6a58d17fe4b4b956a34a556a2506285f0d4ca81eef84d92e7ce41a"
    }
  },
  {
    "ts": null,
    "headline": "Tempus inks $81M Paige buyout to support AI model development",
    "summary": "CEO Eric Lefkofsky said that buying Paige “substantially accelerates” Tempus’ effort to build the largest foundation model in oncology.",
    "url": "https://finnhub.io/api/news?id=7fdf8c5c5dd2b4e90504bd3a7c62fa6e71dea3c28d62bec811109d60e126e4ba",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756202400,
      "headline": "Tempus inks $81M Paige buyout to support AI model development",
      "id": 136526099,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DGX",
      "source": "Yahoo",
      "summary": "CEO Eric Lefkofsky said that buying Paige “substantially accelerates” Tempus’ effort to build the largest foundation model in oncology.",
      "url": "https://finnhub.io/api/news?id=7fdf8c5c5dd2b4e90504bd3a7c62fa6e71dea3c28d62bec811109d60e126e4ba"
    }
  }
]